The main cost drivers in dementia: a systematic review

Schaller, Sandra; Mauskopf, Josephine; Kriza, Christine; Wahlster, Philip; Kolominsky-Rabas, Peter

doi:10.1002/gps.4198

Cited by 175 publications

(188 citation statements)

References 61 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…The costs of all individual resource use items at each follow-up visit (6,12, and 18 months) and for the overall 18-month period were summarized for each country to identify the resource use items with the greatest contribution to total societal costs (see Supplementary Table 2). From this analysis, the following items were included in the analysis of resource use differences between countries: caregiver time, community care services, hospital stays, AD medications, financial support received, temporary accommodation, outpatient visits, institutionalization, and missing work days.…”

Section: Discussionmentioning

confidence: 99%

“…Available cost studies from several European countries show a strong positive relationship between disease severity and total costs of care [1,[3][4][5][6][7][8]. Informal care costs form the major component of societal costs for community-dwelling AD dementia patients [8][9][10][11], and the cost of institutional care is the other main cost driver in the long-term care of patients with AD dementia [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

What Drives Country Differences in Cost of Alzheimer’s Disease? An Explanation from Resource Use in the GERAS Study

Reed

Happich

Argimón³

et al. 2017

JAD

View full text Add to dashboard Cite

Abstract.Background: Country differences in resource use and costs of Alzheimer's disease (AD) may be driven by differences in health care systems and resource availability. Objective: To compare country resource utilization drivers of societal costs for AD dementia over 18 months. Methods: GERAS is an observational study in France (n = 419), Germany (n = 550), and the UK (n = 526). Resource use of AD patients and caregivers contributing to >1% of total societal costs (year 2010) was assessed for country differences, adjusting for participant characteristics. Caregiver time spent on basic and instrumental activities of daily living (ADL) contributed the most to societal costs (54% France, 64% Germany, 65% UK). Caregivers in France spent less time on ADL than UK caregivers and missed fewer work days than in other countries. Compared with other countries, patients in France used more community care services overall and were more likely to use home aid. Patients in Germany were least likely to use temporary accommodation or to be institutionalized at 18 months. UK caregivers spent the most time on instrumental ADL, UK patients used fewest outpatient resources, and UK patients/caregivers were most likely to receive financial support. Conclusion: Caregiver time on ADL contributed the most to societal costs and differed across countries, possibly due to use of community care services and institutionalization. Other resources had different patterns of use across countries, reflecting country-specific health and social care systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

What Drives Country Differences in Cost of Alzheimer’s Disease? An Explanation from Resource Use in the GERAS Study

Reed

Happich

Argimón³

et al. 2017

JAD

View full text Add to dashboard Cite

show abstract

“…For this reason, AD causes a huge economic and social impact, generated by the high costs involved in the health care of patients, such as those involved in the utilization of drug therapy and the provision of full-time caregiver (Schaller et al 2014). It is worth mentioning that in the United States of America (USA), about $604 million dollars are invested annually for the assistance of patients with dementia (WHO 2012).…”

Section: Introductionmentioning

confidence: 99%

Alzheimer´s Disease associated with Psychiatric Comorbidities

Garcez

Falchetti

Mina

et al. 2015

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common cause of dementia and has become a severe public health issue. It is estimated that globally, 35.6% of people have some form of dementia. This number is expected to double by 2030, and possibly even triple by 2050. The disease is associated with deficits in cognition/ memory and a reduced ability in coping with everyday life. Moreover, patients can experience behavioral alterations such as mood swings, depression and hallucinations. Therefore, it is common to find the presence of neuropsychiatric comorbidities such as depression, schizophrenia and bipolar disorder during the course or development of AD. These disorders can become severe enough to interfere with the patients daily functioning, and can worsen the course of the disease. However, little is known about the causal relationship between psychiatric comorbidities and AD, or the reasons for the predisposition of some individuals to such disorders. Therefore, the purpose of this review is to clarify the causal relationship between depression, schizophrenia and bipolar disorder with AD.

show abstract

“…Although a number of recent studies have investigated its economic impact [29,[46][47][48][49], no best practice method for costing has been agreed on to date. It is evident that more data are required to estimate this economic burden accurately, particularly in countries such as China, where methods applied in developed countries may not be appropriate.…”

Section: Discussionmentioning

confidence: 99%